Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | JAK2 LOH JAK2 inact mut |
Therapy | VSV-delta51 |
Indication/Tumor Type | melanoma |
Response Type | predicted - sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
JAK2 LOH JAK2 inact mut | melanoma | predicted - sensitive | VSV-delta51 | Preclinical - Patient cell culture | Actionable | In a preclinical study, a melanoma patient-derived cell line harboring an inactivating JAK2 mutation and JAK2 loss of heterozygosity resulted in sensitivity to treatment with an oncolytic virus, VSV-delta51, in culture (PMID: 33593882). | 33593882 |
PubMed Id | Reference Title | Details |
---|---|---|
(33593882) | Mutations in the IFNγ-JAK-STAT Pathway Causing Resistance to Immune Checkpoint Inhibitors in Melanoma Increase Sensitivity to Oncolytic Virus Treatment. | Full reference... |